Group 1 - A-shares experienced significant activity on August 5, with 68 stocks hitting the daily limit up and 2 stocks hitting the limit down [1] - The human brain engineering concept saw active trading, with Innovation Medical reaching the limit up [1] - The PEEK materials concept strengthened, leading to limit up performances for Zhongxin Fluorine Materials and Xinhan New Materials [1] Group 2 - *ST Yuancheng and Honghe Technology both hit the limit down [2]

格隆汇8月5日｜A股市场脑机接口概念股走强，其中，翔宇医疗涨近12%，创新医疗涨超6%，普利特、 爱朋医疗涨超5%，泰和科技涨超4%，熵基科技涨超3%。 ...

2025年1月-3月，创新医疗实现营业收入1.93亿元，同比减少3.98%；归属净利润-1393.74万元，同比减 少368.03%。 来源：金融界 8月5日，创新医疗盘中10.03%涨停，截至14:00，报16.23元/股，成交13.67亿元，换手率21.23%，总市 值71.62亿元。 资料显示，创新医疗管理股份有限公司位于浙江省诸暨市山下湖镇郑家湖村，公司的主营业务是提供医 疗服务，旗下包括建华医院、康华医院、福恬医院和明珠医院四家医疗机构，致力于满足患者需求和提 高医疗质量。公司通过精细化管理，科室建设，人才引培等方式以提升核心竞争力，同时关注行业政 策，进行供应链整合，以优化医疗资源和提高治疗效果。 截至3月31日，创新医疗股东户数6.82万，人均流通股6108股。 ...

创新医疗主要涉及脑机接口、医疗服务、医疗器械、人工智能医疗等概念板块。 注：本内容由算法自动生成，不构成投资建议。 根据异动分析，可能的影响因素如下： 国家医保局制定新上市药品首发价格机制，新增"脑机接口置入费""脑机接口适配费"等价格项目，脑机 接口技术成熟获批进入临床后可快速进入临床应用并收费；创新医疗为国内首个植入式脑机接口多中心 临床试验（2024年6月获批，针对高位截瘫）持有者，拥有Ⅲ类医疗器械注册证（癫痫干预系统），落 地场景包括天坛医院临床治疗、泰康养老社区监护。 截至14时0分，创新医疗涨幅为10.03%，最新价16.23元，总市值71.62亿元，封板资金11.88亿元，成交 额13.86亿元，换手率21.52%，所属行业为医疗服务。 ...

机构表示，脑机接口已历经五十年发展历程，多国为期十年的前期投入已助力脑机接口技术和产业从应 用萌芽期迈入普及期，有望在十年内实现"应用解决方案效果良好，多类解决方案走向成熟的目标"。脑 机接口是事关经济社会发展的战略性领域，其深化发展有利于我国在未来产业科技竞争中抢占制高点。 消息面上，此前有报道称，苹果公司正在与脑机接口公司合作开发"使用大脑信号操纵苹果设备"的技术 标准。周一公布的一段展示视频，首次演示了这项技术的进展。视频显示，作为这场未知试验的参与 者，患有渐冻症的马克.杰克逊在2023年成为首批植入Stentrode的患者。他现在仅凭意念，就能在iPad的 屏幕上选择目标，打开应用程序并撰写信息。 脑机接口概念5日盘中发力上扬，截至发稿，翔宇医疗涨超16%，创新医疗（002173）涨停，爱朋医疗 （300753）涨超8%，倍益康等涨超5%。 ...

Group 1 - The brain engineering concept experienced significant market activity, with several companies in the sector seeing notable stock price increases [1] - Innovation Medical (002173) reached the daily limit increase, indicating strong investor interest [1] - Xiangyu Medical saw a rise of over 15%, reflecting positive market sentiment towards the brain engineering sector [1] Group 2 - Other companies such as Aipeng Medical (300753), Sanbo Brain Science (301293), and Entropy Technology (301330) also experienced slight increases in their stock prices, contributing to the overall positive trend in the industry [1]

Group 1 - The core stock price of Innovation Medical on August 4 was 14.75 yuan, down 0.17 yuan or 1.14% from the previous trading day [1] - The trading volume on that day was 566,532 hands, with a transaction amount of 815 million yuan [1] - Innovation Medical operates in the healthcare service sector, focusing on medical health industry investment and medical services, providing comprehensive medical services through its medical institutions [1] Group 2 - The Zhejiang University Brain-Machine Intelligence National Key Laboratory recently launched a new generation of neuromorphic brain-like computer "Wukong," with neuron scale approaching that of a macaque brain [1] - The National Medical Insurance Administration has established a billing project for brain-machine interface medical services in March this year, with the global brain-machine interface medical application market expected to reach 40 billion USD by 2030 [1] - Innovation Medical is regarded as a related concept stock and has attracted market attention due to developments in the brain-machine interface sector [1] Group 3 - On August 4, the net outflow of main funds for Innovation Medical was 58.69 million yuan, accounting for 0.96% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds reached 183.42 million yuan, representing 2.99% of the circulating market value [1]

Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed C Fund, which has shown significant returns over various time frames, with a year-to-date return of 80.47% and a recent one-month return of 10.05% [1] - As of June 30, 2025, the fund's total assets amounted to 2.686 billion yuan, indicating a substantial scale for a fund established in October 2020 [1] - The top ten stock holdings of the fund account for a combined 62.83%, with notable investments in companies such as Innovent Biologics (8.33%) and Hengrui Medicine (8.08%) [1] Group 2 - The fund manager, Zheng Ning, has a strong background in the investment industry, having previously held senior positions at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022, and has also taken on managerial roles for other funds within the Zhongyin family [2]

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 13.30 | -6.60% | 97.13万 | 13.47 乙 | | 688710 | 益诺思 | 42.93 | -4.34% | 2.77万 | 1.21亿 | | 300725 | 药石科技 | 47.25 | -4.08% | 22.57万 | 10.92亿 | | 603456 | 九州药业 | 18.32 | -3.48% | 63.91万 | 11.90亿 | | 603259 | 药明康德 | 93.00 | -3.40% | 89.33万 | 83.98亿 | | 300759 | 康龙化成 | 30.10 | -3.22% | 61.22万 | 18.70亿 | | 688202 | 美迪西 | 61.60 | -2.84% | 7.28万 | 4.55 Z | | 002173 | 创新医疗 | 14.92 | -2.74% | 81.94万 | 12.53亿 | | 002821 | 司 ...